Restart Life Sciences (NMLSF) Financial Statements
Restart Life Sciences Financial Overview
Restart Life Sciences's market cap is currently $3.58M. The company's EPS TTM is $-0.03; its P/E ratio is -1.96; Restart Life Sciences is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 25.41K | $ -3.79K | $ -5.00K |
| Operating Income | $ -1.35M | $ -658.51K | $ -1.23M | $ -1.94M | $ -2.93M |
| EBITDA | $ -1.34M | $ -656.20K | $ -1.20M | $ -1.84M | $ -2.68M |
| Net Income | $ -1.39M | $ 224.75K | $ -1.22M | $ -3.76M | $ -2.68M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.65M | $ 169.95K | $ 8.09K | $ 266.52K | $ 218.73K |
| Total Assets | $ 1.77M | $ 190.40K | $ 31.06K | $ 296.79K | $ 881.16K |
| Total Debt | $ 245.36K | $ 79.88K | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -1.35M | $ 68.56K | $ -8.09K | $ -266.52K | $ -218.73K |
| Total Liabilities | $ 480.21K | $ 489.47K | $ 841.66K | $ 255.44K | $ 422.06K |
| Stockholders' Equity | $ 1.29M | $ -299.07K | $ -810.60K | $ 41.34K | $ 459.10K |
| Cash Flow | |||||
| Free Cash Flow | $ -717.22K | $ -71.77K | $ -277.53K | $ -1.44M | $ -1.95M |
| Operating Cash Flow | $ -717.22K | $ -71.77K | $ -277.53K | $ -1.44M | $ -1.95M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 29.64K |
| Financing Cash Flow | $ 2.30M | $ 75.00K | $ 19.10K | $ 1.49M | $ 0.00 |
Currency in CAD